The role of Smad7 in oral mucositis

Abstract

Oral mucositis, a severe oral ulceration, is a common toxic effect of radio- or chemoradio-therapy and a limiting factor to using the maximum dose of radiation for effective cancer treatment. Among cancer patients, at least 40% and up to 70%, of individuals treated with standard chemotherapy regimens or upper-body radiation, develop oral mucositis. To date, there is no FDA approved drug to treat oral mucositis in cancer patients. The key challenges for oral mucositis treatment are to repair and protect ulcerated oral mucosa without promoting cancer cell growth. Oral mucositis is the result of complex, multifaceted pathobiology, involving a series of signaling pathways and a chain of interactions between the epithelium and submucosa. Among those pathways and interactions, the activation of nuclear factor-kappa B (NF-κB) is critical to the inflammation process of oral mucositis. We recently found that activation of TGFβ(transforming growth factor β) signaling is associated with the development of oral mucositis. Smad7, the negative regulator of TGFβ signaling, inhibits both NF-κB and TGFβ activation and thus plays a pivotal role in the prevention and treatment of oral mucositis by attenuating growth inhibition, apoptosis, and inflammation while promoting epithelial migration. The major objective of this review is to evaluate the known functions of Smad7, with a particular focus on its molecular mechanisms and its function in blocking multiple pathological processes in oral mucositis.

Keywords

Smad7 / oral mucositis / cancer / TGFβ / NF-κB

References

[1] Azuma H, Ehata S, Miyazaki H, Watabe T, Maruyama O, Imamura T, Sakamoto T, Kiyama S, Kiyama Y, Ubai T (2005) Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. J Natl Cancer Inst97: 1734-1746

[2] Barasch A, Peterson DE (2003) Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol: 91-100

[3] Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer8: 33-39

[4] Boulay JL, Mild G, Reuter J, Lagrange M, Terracciano L, Lowy A, Laffer U, Orth B, Metzger U, Stamm B (2001) Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7. Genes Chromosomes Cancer31: 240-247

[5] Castilho RM, Squarize CH, Leelahavanichkul K, Zheng Y, Bugge T, Gutkind JS (2010) Rac1 is required for epithelial stem cell function during dermal and oral mucosal wound healing but not for tissue homeostasis in mice. PLoS One5: e10503

[6] Chen HY, Huang XR, Wang W, Li JH, Heuchel RL, Chung AC, Lan HY (2011) The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes60: 590-601

[7] Chung AC, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY (2009) Disruption of the Smad7 gene promotes renal flbrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant24: 1443-1454

[8] Denham JW, Hauer-Jensen M (2002) The radiotherapeutic injury—a complex ‘wound’. Radiother Oncol63: 129-145

[9] Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature425: 577-584

[10] DiVito KA, Trabosh VA, Chen YS, Chen Y, Albanese C, Javelaud D, Mauviel A, Simbulan-Rosenthal CM, Rosenthal DS (2010) Smad7 restricts melanoma invasion by restoring N-cadherin expression and establishing heterotypic cell-cell interactions in vivo. Pigment Cell Melanoma Res23: 795-808

[11] Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K (2001) Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem276: 12477-12480

[12] Edlund S, Bu S, Schuster N, Aspenstrom P, Heuchel R, Heldin NE, ten Dijke P, Heldin CH, Landstrom M (2003) Transforming growth factor beta1-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell14(2): 529-544

[13] Ekman M, Mu Y, Lee SY, Edlund S, Kozakai T, Thakur N, Tran H, Qian J, Groeden J, Heldin CH (2012) APC and Smad7 link TGFbeta type I receptors to the microtubule system to promote cell migration. Mol Biol Cell23: 2109-2121

[14] Epstein JB, Gorsky M, Guglietta A, Le N, Sonis ST (2000) The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer89: 2258-2265

[15] Epstein JB, Silverman S Jr, Paggiarino DA, Crockett S, Schubert MM, Senzer NN, Lockhart PB, Gallagher MJ, Peterson DE, Leveque FG (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer92: 875-885

[16] Feng XH, Derynck R (2005) Speciflcity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol21: 659-693

[17] Groneberg DA, Witt H, Adcock IM, Hansen G, Springer J (2004) Smads as intracellular mediators of airway inflammation. Exp Lung Res30: 223-250

[18] Halder SK, Beauchamp RD, Datta PK (2005) Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp Cell Res307: 231-246

[19] Han G, Li F, Ten Dijke P, Wang XJ (2011) Temporal smad7 transgene induction in mouse epidermis accelerates skin wound healing. Am J Pathol179: 1768-1779

[20] Han G, Bian L, Li F, Cotrim A, Wang D, Lu J, Deng Y, Bird G, Sowers A, Mitchell JB (2013) Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med19: 421-428

[21] Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA Jr, Wrana JL (1997) The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell89: 1165-1173

[22] He W, Cao T, Smith DA, Myers TE, Wang XJ (2001) Smads mediate signaling of the TGFá superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis. Oncogene20: 471-483

[23] He W, Li AG, Wang D, Han S, Zheng B, Goumans MJ, Ten Dijke P, Wang XJ (2002) Overexpression of Smad7 results in severe pathological alterations in multiple epithelial tissues. EMBO J21: 2580-2590

[24] Henke M, Alfonsi M, Foa P, Giralt J, Bardet E, Cerezo L, Salzwimmer M, Lizambri R, Emmerson L, Chen MG (2011) Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol29: 2815-2820

[25] Hong S, Lim S, Li AG, Lee C, Lee YS, Lee EK, Park SH, Wang XJ, Kim SJ (2007) Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2. Nat Immunol8: 504-513

[26] Javelaud D, Delmas V, Moller M, Sextius P, Andre J, Menashi S, Larue L, Mauviel A (2005) Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene24: 7624-7629

[27] Jyung RW, Wu L, Pierce GF, Mustoe TA (1994) Granulocyte-macrophage colony-stimulating factor and granulocyte colonystimulating factor: differential action on incisional wound healing. Surgery115: 325-334

[28] Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFbeta receptor for degradation. Mol Cell6: 1365-1375

[29] Khuntia D, Harris J, Bentzen SM, Kies MS, Meyers JN, Foote RL, Machtay M, Straube WL (2008) Increased oral mucositis after IMRT versus non-IMRT when combined with cetuximab and cisplatin or docetaxel for Head and neck cancer: preliminary results of RTOG 0234. Int J Radiat Oncol72: 839

[30] Kim YH, Lee HS, Lee HJ, Hur K, Kim WH, Bang YJ, Kim SJ, Lee KU, Choe KJ, Yang HK (2004) Prognostic signiflcance of the expression of Smad4 and Smad7 in human gastric carcinomas. Ann Oncol15(4): 574-580

[31] Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D, Korc M(1999) The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene18: 5363-5372

[32] Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S (1993) Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA90: 770-774

[33] Lalla RV, Peterson DE (2006) Treatment of mucositis, including new medications. Cancer J12: 348-354

[34] Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer120: 1453-1461

[35] Lawson CD, Burridge K (2014) The on-off relationship of Rho and Rac during integrin-mediated adhesion and cell migration. Small GTPases5: e27958

[36] Le QT, Kim HE, Schneider CJ, Murakozy G, Skladowski K, Reinisch S, Chen Y, Hickey M, Mo M, Chen MG (2011) Palifermin reduces severe mucositis in deflnitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol29: 2808-2814

[37] Leivonen SK, Ala-Aho R, Koli K, Grenman R, Peltonen J, Kahari VM (2006) Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells. Oncogene25: 2588-2600

[38] Li AG, Lu SL, Zhang MX, Deng C, Wang XJ (2004a) Smad3 knockout mice exhibit a resistance to skin chemical carcinogenesis. Cancer Res64: 7836-7845

[39] Li AG, Wang D, Feng XH, Wang XJ (2004b) Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J23: 1770-1781

[40] Li Q, Zhang D, Wang Y, Sun P, Hou X, Larner J, Xiong W, Mi J (2013) MiR-21/Smad 7 signaling determines TGF-beta1-induced CAF formation. Sci Rep3: 2038

[41] Lin X, Liang M, Feng XH (2000) Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem275: 36818-36822

[42] Liu X, Lee J, Cooley M, Bhogte E, Hartley S, Glick A (2003) Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Cancer Res63: 7760-7768

[43] Liu IM, Schilling SH, Knouse KA, Choy L, Derynck R, Wang XF (2009) TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J28: 88-98

[44] Lu SL, Reh D, Li AG, Woods J, Corless CL, Kulesz-Martin M, Wang XJ (2004) Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res64: 4405-4410

[45] Luo X, Ding Q, Wang M, Li Z, Mao K, Sun B, Pan Y, Wang Z, Zang YQ, Chen Y (2010) In vivo disruption of TGF-beta signaling by Smad7 in airway epithelium alleviates allergic asthma but aggravates lung carcinogenesis in mouse. PLoS One5: e10149

[46] Mallawaarachchi CM, Weissberg PL, Siow RC (2005) Smad7 gene transfer attenuates adventitial cell migration and vascular remodeling after balloon injury. Arterioscler ThrombVasc Biol25: 1383-1387

[47] Massague J, Gomis RR (2006) The logic of TGFbeta signaling. FEBS Lett580: 2811-2820

[48] Migliorati C, Hewson I, Lalla RV, Antunes HS, Estilo CL, Hodgson B, Lopes NN, Schubert MM, Bowen J, Elad S (2013) Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer21: 333-341

[49] Monteleone G, Pallone F, MacDonald TT (2004) Smad7 in TGFbeta-mediated negative regulation of gut inflammation. Trends Immunol25: 513-517

[50] Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH (1997) Identiflcation of Smad7, a TGFbeta-inducible antagonist of TGFbeta signalling. Nature389: 631-635

[51] Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias VE, Niscola P, Riesenbeck D, Stokman M, Tissing W, Yeoh E (2013) Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer21: 3179-3189

[52] Park S, Kang JM, Kim SJ, Kim H, Hong S, Lee YJ (2014) Smad7 enhances ATM activity by facilitating the interaction between ATM and Mre11-Rad50-Nbs1 complex in DNA double-strand break repair. Cell Mol Life Sci.

[53] Peterson DE, Ohrn K, Bowen J, Fliedner M, Lees J, Loprinzi C, Mori T, Osaguona A, Weikel DS, Elad S (2013) Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer21: 327-332

[54] Pittelkow MR, Coffey RJ Jr, Moses HJ (1988) Keratinocytes produce and are regulated by transforming growth factors. Ann NY Acad Sci548: 211-224

[55] Raber-Durlacher JE, von Bultzingslowen I, Logan RM, Bowen J, Al-Azri AR, Everaus H, Gerber E, Gomez JG, Pettersson BG, Soga Y (2013) Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer21: 343-355

[56] Rizzo A, Waldner MJ, Stolfl C, Sarra M, Fina D, Becker C, Neurath MF, Macdonald TT, Pallone F, Monteleone G (2011) Smad7 expression in T cells prevents colitis-associated cancer. Cancer Res71: 7423-7432

[57] Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer100: 2026-2046

[58] Saika S, Ikeda K, Yamanaka O, Miyamoto T, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, Nakajima Y, Kao WW (2005) Expression of Smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali. Am J Pathol166: 1405-1418

[59] Scully C, Epstein J, Sonis S (2003) Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck25: 1057-1070

[60] Scully C, Sonis S, Diz PD (2006) Oral mucositis. Oral Dis12: 229-241

[61] Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D (1992) Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature359: 693-699

[62] Singer AJ, Clark RA (1999) Cutaneous wound healing. N Engl J Med341: 738-746

[63] Sonis ST (2002) The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med13: 380-389

[64] Sonis ST (2004a) A biological approach to mucositis. J Support Oncol 2:21-32 discussion35-26

[65] Sonis ST (2004b) The pathobiology of mucositis. Nat Rev Cancer4: 277-284

[66] Sonis ST (2009) Efflcacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. Core Evid4: 199-205

[67] Sonis ST (2010) Efflcacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. Core Evid4: 199-205

[68] Sonis ST (2013) Oral mucositis in head and neck cancer: risk, biology, and management. Am Soc Clin Oncol Educ Book.

[69] Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S (2008) Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer112: 1600-1606

[70] Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med351: 2590-2598

[71] Treister N, Sonis S (2008) Oral mucositis. In: Ettingeesr DS (ed) Cancer and drug discovery development: supportive care in cancer therapy. Humana Press, Totowa, pp 193-211

[72] Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol66: 253-262

[73] Vagliano L, Feraut C, Gobetto G, Trunflo A, Errico A, Campani V, Costazza G, Mega A, Matozzo V, Berni M (2011) Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT—results of a multicentre study. Bone Marrow Transplant46: 727-732

[74] Vera-Llonch M, Oster G, Hagiwara M, Sonis S (2006) Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer106: 329-336

[75] Wang W, Huang XR, Li AG, Liu F, Li JH, Truong LD, Wang XJ, Lan HY (2005) Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol16: 1371-1383

[76] Wang XJ, Han G, Owens P, Siddiqui Y, Li AG (2006) Role of TGF beta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc11: 112-117

[77] Wang J, Zhao J, Chu ES, Mok MT, Go MY, Man K, Heuchel R, Lan HY, Chang Z, Sung JJ (2013) Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro. J Pathol230: 441-452

[78] Weigelt C, Haas R, Kobbe G (2011) Pharmacokinetic evaluation of palifermin for mucosal protection from chemotherapy and radiation. Expert Opin Drug Metab Toxicol7: 505-515

[79] Wu HG, Song SY, Kim YS, Oh YT, Lee CG, Keum KC, Ahn YC, Lee SW (2009) Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial. Cancer115: 3699-3708

[80] Wu JC, Beale KK, Ma JD (2010) Evaluation of current and upcoming therapies in oral mucositis prevention. Future Oncol6: 1751-1770

[81] Yan X, Chen YG (2011) Smad7: not only a regulator, but also a cross-talk mediator of TGF-beta signalling. Biochem J434: 1-10

[82] Yarom N, Ariyawardana A, Hovan A, Barasch A, Jarvis V, Jensen SB, Zadik Y, Elad S, Bowen J, Lalla RV (2013) Systematic review of natural agents for the management of oral mucositis in cancer patients. Support Care Cancer21: 3209-3221

RIGHTS & PERMISSIONS

2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.